Assessment of Large-Sample Unit-Dose Uniformity Tests - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Assessment of Large-Sample Unit-Dose Uniformity Tests
The authors describe the concept of the limiting discriminatory threshold (LDT) as an objective means of evaluating the inherent quality requirement of a large-sample content-uniformity test.


Pharmaceutical Technology
Volume 35, Issue 10, pp. 82-92

Discussion and conclusion

This article introduced and illustrated the LDT criterion for evaluating the performance and efficiency of large-sample UDU test proposals. The intent was not to introduce a new proposal or to provide a definitive evaluation of any specific large-sample UDU test, but merely to suggest an objective way of comparing test proposals and of ensuring that large-sample UDU tests will meet or exceed the quality standard set by the hUSP test.

The LDTs for parametric tests generally depend on the parameters of the assumed population distribution. For illustration, LDTs were examined for normal and t distributions. In principle, LDTs could be evaluated against other distributions that include skewness (e.g., log normal) or bimodality (e.g., mixed normal). The authors used 85–115% LC as the range of interest for defining coverage, although other ranges (e.g., 75–125% LC) may also be of interest. Furthermore, the LDT approach could be extended to quality measures other than coverage, or to multivariate measures.

It may not always be possible to calculate the LDT of a test directly by algebra and intuitive arguments. However, the LDT can always be obtained by extrapolation to a large sample size using simulation. This article showed how coverage corresponding to the 10% and 90% acceptance probabilities varied as a function of the sample size, which can be used to evaluate and compare the power and efficiency of competing tests.

To ensure that quality standards are maintained at an appropriate level, it is imperative that common quality criteria be identified and adopted. This article presents the LDT approach to assist in reaching this common goal.

Yanhui Hu* is principal process development engineer, and David LeBlond is senior statistician, both at Abbott Laboratories, D050Z, AMJ23, Abbott Park, IL 60064, tel. 847.938.8885,
.

*To whom all correspondence should be addressed.

Submitted: Apr. 4, 2011. Accepted: June 13, 2011.

References

1. USP 33–NF 28 Reissue, General Chapter <905>, "Uniformity of Dosage Units" (US Pharmacopeial Convention, Rockville, MD, 2010).

2. D. Sandell, et al., Drug Inf. J. 40 (3), 337–344 (2006).

3. J. Bergum and K.E. Vukovinsky, Pharm. Technol. 34 (11), 72–79 (2010).

4. M. Diener et al., Drug Inf. J. 43 (3), 287–298 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here